- Home
- EDBL vs INM Comparison
EDBL vs INM Comparison
Compare EDBL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDBL
- INM
- Stock Information
- Founded
- EDBL 2020
- INM 1981
- Country
- EDBL United States
- INM Canada
- Employees
- EDBL N/A
- INM N/A
- Industry
- EDBL Farming/Seeds/Milling
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- EDBL Consumer Staples
- INM Health Care
- Exchange
- EDBL Nasdaq
- INM Nasdaq
- Market Cap
- EDBL 2.7M
- INM 3.2M
- IPO Year
- EDBL 2022
- INM N/A
- Fundamental
- Price
- EDBL $2.26
- INM $2.30
- Analyst Decision
- EDBL
- INM
- Analyst Count
- EDBL 0
- INM 0
- Target Price
- EDBL N/A
- INM N/A
- AVG Volume (30 Days)
- EDBL 73.0K
- INM 46.6K
- Earning Date
- EDBL 05-15-2025
- INM 05-13-2025
- Dividend Yield
- EDBL N/A
- INM N/A
- EPS Growth
- EDBL N/A
- INM N/A
- EPS
- EDBL N/A
- INM N/A
- Revenue
- EDBL $13,857,000.00
- INM $4,832,013.00
- Revenue This Year
- EDBL $29.56
- INM N/A
- Revenue Next Year
- EDBL $20.00
- INM N/A
- P/E Ratio
- EDBL N/A
- INM N/A
- Revenue Growth
- EDBL N/A
- INM N/A
- 52 Week Low
- EDBL $1.82
- INM $1.72
- 52 Week High
- EDBL $230.00
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- EDBL 52.38
- INM 34.09
- Support Level
- EDBL $1.87
- INM $2.70
- Resistance Level
- EDBL $2.40
- INM $3.20
- Average True Range (ATR)
- EDBL 0.15
- INM 0.23
- MACD
- EDBL 0.10
- INM -0.05
- Stochastic Oscillator
- EDBL 76.75
- INM 5.26
About EDBL Edible Garden AG Incorporated
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.